# Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

> **NCT00622726** · PHASE2 · UNKNOWN · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 150 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Bevacizumab
- **PROCEDURE:** Conventional Laser for ROP

## Key facts

- **NCT ID:** NCT00622726
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2010-08
- **Final completion:** 2020-08
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622726, "Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00622726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*